References
- Jia JH, Chen KP, Chen SX, et al. Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol 2008;63:757–62
- Xiong F, Xiong C, Yao J, et al. Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. Int J Pharm 2011;421:275–82
- Wang M, Xie C, Cai RL, et al. Studies on antioxidant activities of breviscapine in the cell-free system. Am J Chinese Med 2008;36:1199–207
- Li XL, Li YQ, Yan WM, et al. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med 2004;70:1039–44
- Lin LL, Liu AJ, Liu JG, et al. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharm 2007;50:327–32
- Xiong Z, Liu C, Wang F, et al. Protective effects of breviscapine on ischemic vascular dementia in rats. Biol Pharm Bull 2006;29:1880–5
- Zhong H, Deng Y, Wang X, Yang B. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm 2005;301:15–24
- Hao X, Cheng G, Yu JE, et al. Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats. Die Pharmazie 2005;60:477–8
- Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliver Rev 2012;64:701–5
- Ding Y, Huang GH. Formula screening and optimizing for the dispersible tablets of breviscapine by orthogonal experiment. Zhong Yao Cai 2010;33:455–8
- Fei X, Chen X, Liang G, et al. Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J Drug Target 2009;17:408–14
- Li M, Zheng Y, Shan FY, et al. Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine. Acta Pharmacol Sin 2013;34:1108–15
- Singh B, Bandopadhyay S, Kapil R, et al. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 2009;26:427–521
- Xia H, Qiu F, Zhu S, et al. Isolation and identification of ten metabolites of breviscapine in rat urine. Biol Pharm Bull 2007;30:1308–16
- Gao F, Zhang Z, Bu H, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release 2011;149:168–74
- Chen H, Khemtong C, Yang X, et al. Nanonization strategies for poorly water-soluble drugs, Drug Discov Today 2011;16:354–60
- Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol 2010;27:260–73
- Ma Y, Lin BQ, Li WZ, Hu XF. Studies on absorption kinetics of naringenin in rat intestine. Chin Tradit Patent Med 2012;34:74–7
- Fu Q, Sun J, Ai X, et al. Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption. Int J Pharma 2013;448:290–7
- Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011;37:907–16
- Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man – fact or myth. Pharma Res 1997;14:763–6